KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Liabilities and Shareholders Equity: 2019-2024

Historic Liabilities and Shareholders Equity for Royalty Pharma (RPRX) over the last 6 years, with Dec 2024 value amounting to $18.2 billion.

  • Royalty Pharma's Liabilities and Shareholders Equity rose 7.23% to $19.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $73.5 billion, marking a year-over-year increase of 7.75%. This contributed to the annual value of $18.2 billion for FY2024, which is 11.24% up from last year.
  • As of FY2024, Royalty Pharma's Liabilities and Shareholders Equity stood at $18.2 billion, which was up 11.24% from $16.4 billion recorded in FY2023.
  • In the past 5 years, Royalty Pharma's Liabilities and Shareholders Equity registered a high of $18.2 billion during FY2024, and its lowest value of $16.0 billion during FY2020.
  • Over the past 3 years, Royalty Pharma's median Liabilities and Shareholders Equity value was $16.8 billion (recorded in 2022), while the average stood at $17.1 billion.
  • In the last 5 years, Royalty Pharma's Liabilities and Shareholders Equity increased by 28.68% in 2020 and then declined by 4.01% in 2022.
  • Royalty Pharma's Liabilities and Shareholders Equity (Yearly) stood at $16.0 billion in 2020, then increased by 9.34% to $17.5 billion in 2021, then decreased by 4.01% to $16.8 billion in 2022, then dropped by 2.57% to $16.4 billion in 2023, then rose by 11.24% to $18.2 billion in 2024.